相关实验视频
Updated: May 11, 2026

10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
12.5K
对儿童蛋过敏进行更安全的口服免疫疗法
Fumi Ishikawa1, Yumiko Miyaji1, Kiwako Yamamoto-Hanada1
1Allergy Center, National Center for Child Health and Development, Tokyo, Japan.
The journal of allergy and clinical immunology. Global
|September 2, 2025
概括
与标准的OIT相比,一种使用非常低初始剂量的新口服免疫疗法 (OIT) 在患有蛋过敏的儿童中显示出更好的安全性和更少的不良事件. 这种方法可以为HE过敏提供更安全的治疗选择.
科学领域:
- 过敏和免疫学
- 儿童过敏症
- 免疫疗法
背景情况:
- 对于儿童的蛋过敏,不良反应是口服免疫治疗 (OIT) 的重要障碍.
- 需要更安全的OIT方法来改善治疗的坚持和结果.
研究的目的:
- 对患有HE过敏的儿童进行新型OIT方案的安全性和有效性的评估.
- 将非常低的初始剂量实验治疗 (ET) 与OIT的标准治疗 (ST) 进行比较.
主要方法:
- 进行了二期双盲随机对照试验.
- 患有HE过敏的参与者 (1-18岁) 被随机分配到ET (非常低的起始剂量) 或ST (固定的维持剂量).
- 主要安全性结果:第一次IgE介导即时反应的几天;疗效结果:累计耐受剂量 (CTD) 的变化.
主要成果:
- 这项研究提前结束,但ET组的第一反应时间显著延长 (P = .033).
- 在ET群体中,不良事件发生率较低,这可能改善了治疗的坚持.
- 通过CTD变化测量的疗效无法在不同组之间进行比较.
结论:
- 对于患有HE过敏的儿童来说,使用非常低的初始剂量似乎是一个更安全的方法.
- 这种方法可以减少治疗负担,提高儿科患者的耐受性.
相关概念视频
Vaccinations
Overview
Active versus Passive Immunity
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
Active Immunity
Active immunity refers to the resistance one develops...
Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

